Epoetin Response A total of 121 patients were included in the study. Seventy-two patients (60%) had anemia associated with CKD, and 49 patients (40%) had anemia associated with cancer. Forty-two patients (35%) were in the Responders group, and 79 patients (65%) were in the Nonresponders group. Baseline hemoglobin levels differed significantly between Responders (10 g/dl) [...]
Retrospective chart reviews were conducted for all male patients who began epoetin therapy for anemia secondary to CKD or cancer between January 1, 2002, and December 31, 2003, at the Fargo VA Medical Center. Patients were excluded from the study if (1) they underwent a phlebotomy or multiple transfusions (i.e., on more than one occasion) [...]
INTRODUCTION Anemia frequently occurs in patients with chronic kidney disease (CKD) and in patients with cancer. In those with CKD, anemia is often the result of decreased erythropoietin production by the failing kidneys. Malignancy can lead to anemia because of the myelotoxic effects of chemotherapy and radiation treatments, as well as factors associated with the [...]
She easiest way to get more generic versions of biotechnology (bio-generic) drugs onto the U.S. market would be to pass a law allowing the Food and Drug Administration (FDA) to approve them. The hardest part would then be the need for the FDA to figure out how to structure a sensible approval process.
